---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-013486"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:37:18.464309+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Passage Bio Q2 net loss $23.9M; GM1 gene therapy shows biomarker normalization at Dose 2; cash runway extended

## Summary
- Net loss $23.9M ($0.44/sh) vs $39.5M ($0.73) in Q2 2022.
- Cash and marketable securities $151.5M; cash runway extended into Q4 2025 after restructuring.
- Interim GM1 data: PBGM01 well-tolerated; Dose 2 achieved normal CSF β-Gal activity and GM1 ganglioside levels durable to 12mo.
- First patient dosed at Dose 3 in July 2023; initial safety/biomarker data expected by mid-2024.
- FTD trial PBFT02: initial Cohort 1 data expected Q4 2023; six sites initiated in Brazil, Canada, US.

## SEC filing metadata
- accession: 0001558370-23-013486
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837023013486/0001558370-23-013486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837023013486/pasg-20230807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-013486
- JSON: https://secwatch.observer/filing/0001558370-23-013486.json
- Plain text: https://secwatch.observer/filing/0001558370-23-013486.txt

## Key facts
- Earnings Releases
  Passage BIO, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $23.9 million, or a net loss of $0.44 per basic and diluted share, EPS $0.44 per basic and diluted share.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss was $23.9 million, or a net loss of $0.44 per basic and diluted share
  - EPS: $0.44 per basic and diluted share
  - Result: reported results
  source text: Net loss was $23.9 million, or a net loss of $0.44 per basic and diluted share, for the quarter ended June 30, 2023, compared to $39.5 million, or a net loss of $0.73 per basic and diluted share, for the same quarter in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000155837023013486/0001558370-23-013486-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.